Skip to content

13F-HR filed by Spruce Street Capital LP

Spruce Street Capital LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-13 22:00:43 UTC, with 39 holding rows worth $628,983,538.

Accession
0002050194-26-000006
Filed
2026-11-13
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 39 entries on the cover page, a total value of $628,983,538 stated on the cover page (in dollars after the unit check, H1), rows summing to $628,983,538 with VALUE read as dollars as filed, 13F file number 028-26325. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
KINIKSA PHARMACEUTICALS INTL P ORD SHS CL AG52694109Stock918,070$68,497,203dollars as filed
RELAY THERAPEUTICS INC COM75943R102Stock2,984,125$53,863,456dollars as filed
LB PHARMACEUTICALS INC50180M108COMMON STOCK1,404,779$53,863,456dollars as filed
ALTO NEUROSCIENCE INC COM SHS02157Q109Stock1,676,558$42,802,526dollars as filed
ALKERMES PLCG01767105SHS948,471$38,432,045dollars as filed
ENTERA BIO LTDM40527109SHS11,213,455$32,631,154dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM354,816$31,241,549dollars as filed
SAVARA INC805111101COM5,381,941$27,770,816dollars as filed
ZAI LAB LTD ADR98887Q104ADR1,042,158$27,450,442dollars as filed
RELMADA THERAPEUTICS INC75955J402COMMON STOCK6,912,191$26,058,960dollars as filed
VAXCYTE INC COM92243G108Stock306,047$17,414,074dollars as filed
Obsidian Therapeutics, Inc.67448A106Common Stock, $0.0001 par value per share1,249,943$17,161,717dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock329,006$15,081,635dollars as filed
ENANTA PHARMACEUTICALS INC29251M106COM1,088,731$14,349,475dollars as filed
SURROZEN INC86889P208COMMON STOCK432,040$13,903,047dollars as filed
SAGIMET BIOSCIENCES INC A786700104COMMON STOCK1,400,000$13,832,000dollars as filed
Yarrow Bioscience, Inc.92941V407Common Stock, $0.0001 par value607,382$13,678,243dollars as filed
Inflarx NvN44821101COM6,086,170$10,955,106dollars as filed
KORSANA BIOSCIENCES INC23255M303COMMON STOCK338,951$10,304,110dollars as filed
PERSPECTIVE THERAPEUTICS INC46489V302COMMON STOCK3,693,931$10,158,310dollars as filed
AN2 THERAPEUTICS INC037326105COM1,752,011$9,320,699dollars as filed
INHIBIKASE THERAPEUTICS INC45719W205COMMON STOCK3,581,603$7,360,194dollars as filed
SAB BIOTHERAPEUTICS INC78397T202COMMON STOCK2,198,502$6,969,251dollars as filed
CENTURY THERAPEUTICS INC15673T100COM4,059,054$6,940,982dollars as filed
ERASCA INC COM29479A108Stock422,543$6,194,480dollars as filed
ACHIEVE LIFE SCIENCES INC004468500COMMON STOCK736,637$5,959,393dollars as filed
MINERVA NEUROSCIENCES INC603380205COM NEW1,655,500$5,545,925dollars as filed
Research Alliance Corp Iii Ord Shs Cl AG75226103Common Stock500,000$5,415,000dollars as filed
RESEARCH ALLIANCE CORP IVG75228109CL A ORD SHS450,000$5,400,000dollars as filed
HELIX ACQUISITION CORP IIIG4444S107USD CL A ORD SHS500,000$5,310,000dollars as filed
ATTOVIA THERAPEUTICS INC04987L102COM228,295$3,912,976dollars as filed
ALECTOR INC014442107COMMON STOCK2,101,068$3,886,976dollars as filed
TCGX ACQUISITION CORPG8708J109COM300,000$3,753,000dollars as filed
LEXEO THERAPEUTICS INC52886X107COMMON STOCK928,593$3,138,644dollars as filed
ALUMIS INC022307102COM392,574$2,901,122dollars as filed
CORVUS PHARMACEUTICALS INC221015100COM231,585$2,667,859dollars as filed
JATT II ACQUISITION CORPG50765109ORD SHS160,000$1,799,200dollars as filed
JATT III ACQUISITION CORPG5080G109COM150,000$1,653,000dollars as filed
LeonaBio Inc04746L203COM393,701$1,405,513dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0002050194-26-000006this filing2026-11-13